Fengli Jingqiu Connect The World | CPhI China 2025

CPhI China 2025, the 23rd World Pharmaceutical Ingredients Exhibition, was held as scheduled in Shanghai, featuring elements of Chinese culture. The event brought together industry professionals from both domestic and international backgrounds, facilitating discussions, exchanges, and collaborations. It served as a platform for presenting developments and opportunities related to the global pharmaceutical industry.

 

As a trusted bridge between suppliers and clients, Fengli works exclusively with strategically chosen global partners, each of whom has undergone a rigorous evaluation process to ensure quality, reliability, and compliance.

1.Regulatory compliance is ensured across major markets including China, the U.S., the EU, Japan and other areas. Products are supported with complete registration documents such as DMF, CEP, and COS, facilitating efficient global market access for Chinese clients.

2. In terms of quality control, all raw material suppliers strictly adhere to ICH Q7 and GMP standards, maintaining rigorous oversight of product purity, stability, and impurity levels from the source. This guarantees full traceability and zero defects for every batch.

3. In terms of technological innovation, by developing new synthetic routes and crystal forms, we help domestic generic drug clients gain early access to international markets. Meanwhile, through customized synthesis processes, green chemistry technologies, and continuous manufacturing, we deliver more competitive, high value-added ingredients that meet the diverse needs of our customers.

 

Lipids without limits

IOI Oleo GmbH’s participation reinforced its Asian market strategy and fueled innovation in pharmaceutical lipid excipients through strong industry collaboration. With advanced technology and trusted quality, IOI Oleo drives global drug development forward.

 

Clariant Deepens Its PEG Portfolio

Following the activation of oral-grade API Polyglykol™ 3350 and 4000 on the CDE platform, and approval of Polyglykol™ 6000 by the NMPA, Clariant’s injectable-grade PEG excipient VitiPure™ LEX 3350S has completed CDE registration (Reg. No.: F20240000562). Developed specifically for high-risk pharmaceutical formulations, VitiPure™ LEX 3350S is manufactured to ensure rigorous control of microbial contamination and endotoxin levels, thereby fulfilling the stringent requirements for use in injections, inhalants, suppositories, and ophthalmic preparations.

 

Highlights of Kerry at the CPhI 2025

In addition to traditional lactose and its compound mixtures, Niacet’s pharmaceutical-grade acetate series is widely applied in diabetes treatments—including Insulin, Dialysis Fluids, and Phosphate Binders—as well as in the production of Penicillin, Antibiotics, Hormones, Enzymes, and oral care products.

Key products such as Sodium Acetate, Calcium Acetate, Ammonium Acetate, Potassium Acetate, and Sodium Diacetate meet USP and/or EP standards, with Calcium Acetate and Sodium Acetate Trihydrate produced under c-GMP.

► Calcium acetate is FDA-registered (DMF#18997) and undergoing CDE registration.

► Sodium Acetate CDE API Registration No. Y20190009070, status "A";

► Sodium Acetate CDE Excipient Registration No. F20220000488, status "I".

 

BASF’s Deep Insight into Industry Trends

BASF Asia Pacific and Greater China management met with senior executives from Fengli and Barentz to address key demands in the vitamins and pharmaceutical excipients markets across China and the Asia-Pacific region. The parties reached a strong consensus, particularly on the applications of pharmaceutical- and food-grade vitamins.

With the gradual alleviation of external challenges, BASF and its partners are committed to providing more agile services tailored to local customer requirements. By utilising BASF’s comprehensive global expertise in the fish oil market, they aim to assist Chinese clients in fostering new business growth opportunities.

 

Lubrizol Achieves Progress Despite U.S.–China Trade Tensions

Despite the challenges resulting from U.S.–China trade tensions, Lubrizol demonstrated adaptability at the exhibition by introducing an innovative "30-Minute Webinar" initiative. This approach provided renewed impetus for promoting its core products—Carbopol®, Pemulen®, Noveon®, Apinovex™, and Apisolex™. The webinars further addressed emerging application areas, including injectable drug development, veterinary medicine, and food for special medical purposes (FSMP).

 

Roquette & IFF: Advancing Together for a Healthier Future

With 90 years of expertise, Roquette remains committed to advancing global health and well-being. Its integration with IFF Pharma reinforces a shared focus on innovation, customer needs, and patient care. Together, they aim to deliver advanced pharmaceutical solutions that improve health outcomes worldwide.

 

GRACE Colloidal Silica: Advancing Excellence in Excipient Innovation

GRACE's SYLOID series of mesoporous silica has been fully registered on the CDE platform. AL-1 offers exceptional protection against moisture, helping your formulation remain stable even in highly humid environments. The versatile 244FP—nicknamed the "hexagonal warrior" —is widely regarded as a top choice among silica excipients. Customizable pore structures give SYLOID™ materials enhanced multifunctionality. Meanwhile, XDP3050 and 3150 not only accelerate liquid-to-solid conversion, but also demonstrate strong potential in solid dispersion applications.

 

JRS: The World’s Largest and Only Localized Producer of Microcrystalline Cellulose

With over 140 years of experience and operations in more than 90 locations worldwide, JRS remains an industry leader. At this exhibition, JRS partnered to explore future opportunities, emphasizing its focus on customers and delivering high-quality local service to meet market needs.

 

Exhibition Highlights

Tianjin C&C, Fengli Jingqiu, Fengli Liangjiang, and PuteHealth presented advanced APIs, excipients, and functional food solutions at CPhI Shanghai, garnering significant international interest.

 

I. BLB launches flagship API: High-Quality Lactulose Concentrate Solution (US DMF #042187)

Fengli Jingqiu, in partnership with Baolingbao, has launched a lactulose concentrate solution. The product has been filed with the U.S. FDA (DMF #042187), indicating adherence to international quality standards such as cGMP, and is available to support finished dosage form registrations in overseas markets.

 

II. Advancement in Functional Excipients: Tianjin C&C Introduces Pharma-Grade Cellulose

To address the long-standing reliance on imported key functional excipients, Fengli Jingqiu, in collaboration with Tianjin C&C, introduces a breakthrough solution — high-performance Cellulose Acetate.

 

Key Advantages:

1.Seamless Compatibility: Key properties like acetyl content, viscosity, free acidity, film formation, and permeability match top imported products, allowing easy replacement.

2.Full Regulatory Compliance: Conforms to the requirements of the ChP, USP-NF, and EP.

3.Quality Assurance: Manufactured using established processes and quality control systems to maintain consistent performance.

4.Cost and Supply Advantage: Localized production reduces supply chain risks and costs. It is consistent with national strategies and contributes to the development of domestic sustained-release formulations and coating technologies.

 

III. Strong Foundations for Formulation: Sucroflo® Sugar Fine Granular & Compressible Granules

Fengli Jingqiu, in partnership with Tianjin C&C, delivers high-quality Sugar Fine Granules and Compressible Sugar in the pharmaceutical excipient sector.

 

Key Advantages: Reliable supply, assured quality, cost efficiency.

 

Performance Overview: Sucroflo® Sugar Fine Granular represents China’s first modified sucrose to achieve full compliance with pharmaceutical regulatory standards, and offers outstanding flowability alongside consistent particle size distribution. Compressible Sugar delivers excellent compressibility and flowability, making it an ideal filler and binder for tablets and granules. Both products are designed to meet the specific market requirements for sucrose excipients and are widely utilized in applications including dry suspensions and effervescent tablets.

 

In addition, PuteHealth - a subsidiary of Fengli focused on functional food formulation solutions, injected fresh energy into the exhibition with two innovative products: Hangover Relief & Fresh-Breath Chewing Gum, and C8-MCT Keto Coffee.

 

Amid ongoing shifts in technology, market conditions, and regulatory environments, Fengli Group demonstrates resilient adaptability through its global outlook, technical expertise, and diverse capabilities. By developing high-quality solution platforms tailored to pharmaceutical clients, strengthening its position in established markets, and expanding into emerging regions, Fengli drives sustainable growth and contributes to the industry's continued progression along the global value chain.

 

Looking ahead, Fengli Group remains committed to providing high-quality, compliant, and innovative pharmaceutical APIs, excipients, and intermediates to partners worldwide. This marks the start of a promising yet challenging new chapter. Together, we embrace the future with confidence and a collaborative spirit.